NASDAQ:NBIX - Neurocrine Biosciences Stock Price, Price Target & More

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings results on Monday, April, 30th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by $0.18. The company earned $71.08 million during the quarter, compared to the consensus estimate of $65.17 million. Neurocrine Biosciences had a negative return on equity of 29.67% and a negative net margin of 45.56%. During the same quarter in the prior year, the business earned ($0.90) earnings per share. View Neurocrine Biosciences' Earnings History.

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Neurocrine Biosciences.

13 Wall Street analysts have issued 12 month target prices for Neurocrine Biosciences' shares. Their forecasts range from $79.00 to $120.00. On average, they expect Neurocrine Biosciences' stock price to reach $102.7692 in the next twelve months. View Analyst Ratings for Neurocrine Biosciences.

Some companies that are related to Neurocrine Biosciences include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), argenx (ARGX), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX) and Atara Biotherapeutics (ATRA).

Media stories about NBIX stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neurocrine Biosciences earned a daily sentiment score of 0.12 on Accern's scale. They also gave media coverage about the company an impact score of 46.00 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Neurocrine Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.46%), BB Biotech AG (3.79%), Franklin Resources Inc. (2.62%), Artisan Partners Limited Partnership (2.19%), Wells Fargo & Company MN (1.06%) and OppenheimerFunds Inc. (0.93%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Stephen A Sherwin, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

NBIX stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Millennium Management LLC, Neuberger Berman Group LLC, Dupont Capital Management Corp, DekaBank Deutsche Girozentrale, A.R.T. Advisors LLC, BB Biotech AG and Candriam Luxembourg S.C.A.. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Stephen A Sherwin and William H Rastetter. View Insider Buying and Selling for Neurocrine Biosciences.

NBIX stock was purchased by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Artisan Partners Limited Partnership, Victory Capital Management Inc., BlackRock Inc., Rock Springs Capital Management LP, Point72 Asset Management L.P., Amundi Pioneer Asset Management Inc. and Columbus Circle Investors. View Insider Buying and Selling for Neurocrine Biosciences.

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NBIX stock can currently be purchased for approximately $101.79.

Neurocrine Biosciences has a market capitalization of $9.30 billion and generates $161.63 million in revenue each year. The company earns $-142,540,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Neurocrine Biosciences employs 400 workers across the globe.

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]